Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Phantom said: "If SP isn't over $1 a year from now we have a lot worse problems then delisting."
That bit of truth just about sums it up.
In 2019 they went from about $75 to about $5 and been between $5 and $15 up and down since then.
current SLS P3 trial:
Based on the above data and following review by the FDA, a pivotal Phase 3 clinical trial, the REGAL study, for AML patients in CR2 was commenced in January 2020. The REGAL study is a 1:1 randomized, open-label study comparing GPS monotherapy in the maintenance setting to investigators’ choice best available treatment in AML patients who have achieved hematologic complete remission, with or without thrombocytopenia (CR2/CR2p), after second-line antileukemic therapy and who are deemed ineligible for or unable to undergo allogeneic stem-cell transplantation. The primary endpoint is the overall survival (OS) from the time of study entry. Secondary endpoints include leukemia-free survival, antigen-specific T-cell immune response dynamics, measurable residual disease by multigene array, and assessments of AML clonal evolution and inflammasome molecular signatures in the tumor microenvironment in bone marrow biopsy samples. The study is expected to enroll approximately 116 patients across approximately 50 clinical sites in the United States and Europe.
Their P3 also has Fast Track and Orphan Drug.
https://clinicaltrials.gov/ct2/show/NCT04229979
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : April 2022
We ain't the only ones trying for cures.
We should find out soon how SLS did.
A different P.S.
We CAN NOT be bought out by another company at anything near this insane low price. That would be a very not smart move and will kill all investors.
We CAN NOT raise capital and do a dilution at anything near this insane low price. That would be a very not smart move and will dilute investors like crazy.
The only thing we can do is GREAT AML data that gets the price way up ... and then a partnership to get the price up way more ... and THEN do a dilution (that will be needed soon).
If management/insiders agree to an insane low price buyout or do a dilution BEFORE we get this price back up .........
P.S. I will spare you the years long saga of my TPIV/MRKR buys ..... BUT .... if I buy any more ...... will someone who lives near the space coast in Florida just come over and put a bullet in my head.
SERIOUSLY, I AM DONE BUYING. WAY TOO MUCH was an understatement a long time ago.
I know, you all are laughing right now ..... yeah sure, he will buy more.
NO, really, at this point, with this market, all excess monthly cash flow is going into silver and gold.
I have been playing with what I considered free money. I retired 11 years ago at 54 and with pension, real estate income, etc., I'm fortunate enough to have extra cash every month, so I have been like, "what the hell, buy more MRKR, it's free money anyway".
But "extra" is NOT free, and I worked hard my whole life to get to that "extra" and this BUY MORE MRKR attitude has gotten past stubborn and moved into stupid.
GOOD LUCK to EVERYBODY
Well Bud, I'm rooting for you. I have been reading your posts all this time and I know that you are in (cash wise) deeper than me, and that's DEEP.
I see me and you and hanscott and others still buying and I think of the line from the movie Guardians of the Galaxy when rocket said.
"here we are, a bunch of idiots standing in a circle"
I hope that does not turn out applying to us.
GOOD LUCK.
Hello hanscott. I remember when you said that you put in an order at $0.67.
When I read that I said 2 things, #1 he won't be buying more because I doubt if it gets down to his 0.67. and #2 I'll make sure my order goes through before that 0.67, so I'll put it in for 0.74.
You know the rest for me, bought more at .95, at .80, at .74, and now at .64.
I am just a stubborn idiot, I refuse to quit or give up.
I guess I should have believed that you were correct and just waited until the 0.67 you predicted.
Yes, bought more at .64.
????????????????????????
At this point, anything that works is fine by me.
Well, 6 days ago I wrote ... "I bought more at .95, more today (1/14) at .80, and have an open order at .74."
GUESS WHAT, today my order at .74 was filled. Not really sure if that is good news or bad.
HoHum
Thanks Again
Question for Phantom or AntiMarv or anybody. If I remember correctly, the AML trial (MT-401) was given as a "stand alone" treatment, and it was compared to conventional "standard of care", so they can say ... look MT-401 did SO MUCH better than conventional "standard of care".
But with this for Pancreatic it is: "The Company intends to initiate a Phase 1 multicenter study of MT-601 administered in combination with front-line chemotherapy to patients".
So question is why not "stand alone"? Why in combination with front-line chemotherapy?
I thought one of the purposes of "modern" drugs was to get away from chemo.
And now I guess the results will be determined by ... look MT-601 did SO MUCH better than Chemotherapy alone??? Is that correct?
Thanks
That would be nice.
THANK YOU. I saw that where they said: "Marker developed MT-601, a new product targeting six tumor-associated antigens (PRAME, NY-ESO-1, Survivin, MAGE-A4, SSX2, WT1) highly expressed in pancreatic cancer."
Personally I think that's great. a NEW product. It just makes so much more sense.
I ponder where we would be had Alex Trebek tried MRKR .... and he was still alive today.
I think we would be discussing when we break above $20 a share, instead of $1 a share.
God I hope we are all right, not just for investors, but for Patients ...
for hopefully, several different cancers.
Howdy, it may be silly, but it's true, no one can sell a share unless someone else (maybe stupid like me) buys it.
The LAST thing we want is a buyout when you're down 90% since merger.
What we DO want is a collaboration deal with a big pharma for AML and then kick the rest of the pipeline in to high gear.
I think the big bucks could come from Pancreatic in the future.
I have been investing in biotech for decades. I watch and see what has happened to MRKR share price over the last few years.
I have seen the EXACT same thing with several others that I owned.
Look at charts of (before they took off) of ARWR, ALNY, MRTX, EXEL, SGEN, AVXL and others.
Right now this stock is dust in the wind. Nobody is going to care about MRKR until they announced some giant trial news.
For months and months the price has gone down while people sold, but, somebody is buying every share that they sell, you can't sell into thin air, so someone believes and is buying them shares.
I bought more at .95, more today at .80, and have an open order at .74.
I know, this has been getting old for a LONG time now. And I get older along with it. I guess it's just hope and being stubborn.
As this point, it is so numbing, it's more like playing a fantasy game than reality.
The only problem is, every time I buy more, they won't let me use my fantasy game money.
Hope you have a great 2022.
The first thing I thought about after today's price was, WHY NOW at the beginning of Jan.? It seems like the selling would have been in Dec.
I don't know what is going on except it just seems crazy.
Well, I thought is was smart to buy more at 95 cents.
You've heard the saying ... "fool me once etc. etc."
Geez, now I've been "fooled" about 10 times.
Some people (me) never learn.
OK, It's 2022. Hope all had a great Holiday season.
As we all look forward toward better things, I have a question for those who understand this stuff better than me ... and it concerns a question that I asked Phantom, that he forwarded to Marker.
OK, the subject is Tumor Associated Antigens.
WE (MRKR) use 5 in our cocktail mix.
PRAME, SSX2, MAGEA4, SURVIVIN, and NY-ESO-1.
Now I assume those 5 were chosen after some reseach and determination that those 5 would be the most effective against AML.
I read this on tumor markers: https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-markers-list
BOY, there sure is a lot of them for a whole bunch of different cancers, with different markers for different cancers.
And I read this: "The National Cancer Institute has recently published a priority list of 75 cancer antigens, providing a useful basis for those aiming to test vaccine design and operation against well-documented targets."
And then I read this ... of which ... OUR OWN DR. ALLISON was a part of: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5779623/
So my question is this.
Is using the same 5 antigens (PRAME, SSX2, MAGEA4, SURVIVIN, and NY-ESO-1) on cancers that are not AML still be substantially effective?
We know/assume they are great antigens for AML, but does ANYBODY KNOW they are good antigen targets for ... let's say, Pancreatic, or different blood/bone/brain/etc. cancers?
Or, would a different, more targeted antigen cocktail mix be better?
Anybody have an idea about what BOTH, the added time and the added money would be to research which 5 antigens (out of the 75) would be most effective against Pancreatic (the same kind of research they did to chose the 5 for AML)?
I don't want to intentionally oversimplify the complex FDA preclinical process but, you put some Pancreatic cancer cells in a glass dish, you introduce 1 of the 75 antigens, you see what happens, and then you do that with the other 74.
How long and expensive could that be?
Thank You All, let's have a better 2022.
First, Happy New Year.
Second, Thank You for your comments.
Third, As I have said about a dozen times now, "I hope you are correct".
Fourth, "I’m in too deep to back out now. I’m either sailing off to riches and glory or going down with the ship.", at least you are not alone.
And Fifth, a question that I have asked before but we are now later along in time, so, ...
... with the new trials, do you think they will use the "same" 5 antigen cocktail mix? ... or will they/have they done research so they can use a "new and improved and better and more targeted" antigen cocktail mix?
I don't understand the "same old" approach except that I do realize there will be increased costs with "new and improved", but if you are trying to cure a disease, why not use the 100% medicine as opposed to the 90% medicine, if you get what I mean.
Thank You Again Phantom
Thanks for the laugh.
in more for .95, next open order .74, i must really be getting senile.
HAPPY NEW YEAR TO ALL .... and PLEASE can we have a much better 2022, not just mrkr, everything, covid, the increased hatred amongst those who don't agree, inflation, on the way to 30 trillion in debt.
we are all tired of it, just let it end for the good of ALL OF US.
I like Phantoms answer better than mine. One thing I forgot to mention is that several months back, a bunch of insiders bought on the open market at $1.75 ... and yet here we sit at a buck??
Hello and Happy Holidays to you. Yes, It's been a while. I wish I could give good or positive news. It's just been going downhill for the last couple of years. I think NEA is our only large investor left.
In my opinion, the news for the last couple of years has been the same over and over, which goes something like ...........
Well, no good news now ... BUT, MAYBE ... POSSIBLY ... in a couple of years we MAY, POSSIBLY be able to report good trial results ... MAYBE ... POSSIBLY.
I'm just holding on because basically I am so stubborn, I would rather hold and lose 100%, then give up and sell out at an 80% loss??
Eagle, try to stay well and safe and happy through this Holiday Season and I hope you have a well, safe and happy 2022.
Long, long ago, in a lifetime far away . . .
I read an article about a little known military technology called CDMA, code division multiple access, and how all of America was using TDMA, time division multiple access, and the rest of the world used GSM, global standard for mobile communications.
Long story short, once I understood what the differences were between them, it was obvious that CDMA would take over the world,
and a small company named Qualcomm owned CDMA . . .
Did very good, sold too early, had I just held on to them, I would not be bothered by the amount I'm losing in MRKR now.
Howdy, 2 reasons really. When I put the order in, it was at like $1.20, so something about 95 cents would be a down of about 20% from the then current price. Also the crazy .9559 was for the reason that if I buy "X" thousand shares at that price, it brings my average cost down to a nice round number.
Well, I wasn't going to admit it, but I have had an open order in for a couple of weeks now ... at $0.9559.
Yes, I'm either an idiot, or a glutten for punishment.
Thank You, you are correct, on a new path, I feel a bit better (but not about the share price).
As we are getting close to $1. Just thinking about a bad feeling I had in May 2019, which I posted .........
microcapbiotech Wednesday, 05/01/19 03:48:03 AM
Post #26287
OPINIONS PLEASE - I just saw MRKR videos upsetting to me.
WHY is Marker paying a (hype the junk company) like RedChip to do hype videos for them?
Now, everybody here knows I am all for more exposure and even encouraged it on message boards and blogs, but I get an instant bad feeling in my stomach when I see a company paying hype firms and doing hype videos.
90% of the time, companies using hype firms are garbage (that's why they are using hype firms), and it just feels bad to me.
I mean, if you are a reflection of the company you keep (company as in friends, not as in a business company), then why are we hanging out with a hyper like RedChip?
I really LOVE Markers technology and potential, so would someone (or many someones) PLEASE explain to me why I am wrong about this.
You join ihub in 2008 and this is your first post, so welcome to you.
I'm not sure if the 64K means dollars or shares, but either way, it seems you are part of this long strange trip.
Again, welcome and please continue to contribute your thoughts
"Especially with the cell-phone trading younin's (like my son) with all those "Robin Hood" apps out there now, and the REDDIT Gamblers - see r/GME, plus the impatient "opportunity costs" longs, etc, etc . . . . so long term, value, science-minded BAG-HOLDERS like us are a dying breed???"
I really think that is true.
I believe this came up even pre merger and I asked you to clear up the Baylor who owns what issue.
I don't see how it can be a, let's say, "detrimental" problem because if it was, WHY would NEA buy. They would have to know.
I honestly don't think it's a IP "ownership" problem for 2 reasons.
1 is why would insiders buy because they would know.
2 I think NEA and Aisling etc. would also "know" that answer before they invested.
Here is how sad the situation is. I just did some math. If, hypothetically I was to invest another $13,500 and I bought another 10,000 shares, ... it would only lower my average cost from $6.70 to $4.85.
So, invest more ... to wind up being down what, ONLY 75%.
YEAH, we got good news, and we are up to, ... less than we started on Monday.
dito, except I'm less smart, no degrees, and the bag I'm holding only has about 19,000 shares in it, but I like you, do not understand the price at all.
I do not want to succumb to the "it's being manipulated" by "them".
But, really, what is going on.
Is it big pharma suppressing it because they are scared our technology will take $'s away from them?
Is it big pharma keeping the price deflated so the can buy it cheap when "the time" comes.
Is the market maker doing something to profit.
And how on earth would they do that?
It is not now currently short selling, at least not according to the published numbers.
I just do not know. I have been on this board (originally with a different name) since Tapimmune was small.
Now what, every single legacy project was useless and now we have MRKR tech.
Insiders BUY ... and it goes down.
Patients are living ... and it goes down.
Peter gives a speech ... and it goes down.
In JUNE of this year, we were at $3.77, OK, what the hell has gone SO WRONG that caused it to drop to $1 and change?
What TERRIBLE NEWS did MRKR release to cause a drop of this magnatude?
When everyone was hoping for a post merger one billion market cap, I said no, it should be about 300/400 million.
But, EVEN RIGHT NOW, when you compare to others in the same situation in the same field, we should be about 300/400 million, at least.
Believe me, this ain't my first bomb, there have been very costly others (PPHM, THDO), but in the big picture, I can't complain, everything I got came from stocks and real estate investing.
But, that doesn't make this MRKR situation SUCK any less.
In one sense, it's just all part of the deal.
On another board (ELMS) on this website, just yesterday, I made a comparison between 2 other stocks that I hold.
#1 has a market cap of 1 billion, #2 has a market cap of 5 billion, ... and it makes NO SENSE at all.
#1 is currently producing product, #2 may start to produce in 2025/2026.
Demand for #1 will be about 100 times than for #2.
Yet #2 is value at 5 times #1.
Makes no sense, just like MRKR.
Good Luck to us all.
or ... before the end of November?
I just read that MRKR went down to $1.15 after hours:
Marker Therapeutics (NASDAQ:MRKR) shares fell 8.74% to $1.15. The company's market cap stands at $95.5 million.
I see 11 patients with 2 relapses. What will the market say.
MRKR hit a double, or MRKR hit a triple.
The problem is, for reasons I don't understand, unless MRKR hits home runs and grand slams, the market just shrugs it off, like no big deal.
No big deal, people are living in remission for 20/30/40/50 months now, nothing to see here?????????
Not that it should mean anything to anybody, but, I'm holding the stock, the warrants, and the 1/23 $10 call options on ELMS.
Apples to apples, this is way too cheap. Even if you admit that it's peers may be over valued, it is still way too cheap.
Actually producing product compared to Canoo (producing in 2024) or Lordstown or Workhorse???
Is it the "China" connection that maybe investors don't like and that is keeping the price down?
I don't know why.
OK, Amazon is buying from Rivivan. OK, who is UPS and FEDEX and the 10 million pizza/food/florist/uber/lyft/doordash/instacart/etc./etc./etc. delivery stores going to buy from.
ELMS is lowest cost, already sold 30,000 in Asia, is up and running and producing NOW.
The main problem right now is that the average investor has never even heard of ELMS.
If in 2022, they get a couple of decent order contracts, a little bit of mainsteam publication and exposure, maybe a couple of mentions on CNBC, this may end 2022 exponentially higher than this pitiful price.
It is not my intention to promote it here, but I will mention another stock I own just as a comparison.
JOBY (basically flying electric taxis and cars) has a market cap of 5 Billion. ELMS is 1 Billion. ELMS is driving on the road RIGHT NOW, JOBY may be flying in 5 years.
If you look at cost/demand of each product ...
OK so demand for ELMS van should be about 100 times more than flying taxis (at least) that won't even exist for many more years ... yet JOBY market cap is 5 times higher than ELMS??????????
What am I missing here??????????